How CD95 keeps NF-κB switched off in triple-negative breast cancer — and what its loss unleashes
GeoMx DSP analysis of tumor and stromal compartments in pre-treatment NSCLC samples
Immune checkpoint blockers have transformed the therapeutic landscape of oncology. In particular, therapies targeting the PD-1/PD-L1 axis have demonstrated major anti-tumor activity and are now approved across several solid tumors, including non-small cell lung cancer. However, most patients treated with PD-1 or PD-L1 inhibitors do not derive clinical benefit. There is therefore a critical need […]
How CD95/Fas helps triple-negative breast cancer escape NK-cell control in preclinical models
How mature TLSs identify solid tumor patients more likely to benefit from PD-1 blockade
How plasma LIF predicts immune-checkpoint blockade resistance and a TLS-poor tumor microenvironment
How BAF/PBAF chromatin-remodeler mutations predict better checkpoint-inhibitor outcomes — and point toward combination strategies
“GPCR-ome” modulation upon PD1 / PDL1 axis blockade
Background Immunotherapy represents a novel weapon in the cancer armamentarium, with unprecedented responses observed in several indications, including metastatic melanoma and lung cancer. However, the limited response rate, accounting for approximately 30%, requires further optimization and calls for a better understanding of the mechanisms underlying sensitivity to immune checkpoint inhibitors. G protein-coupled receptors (GPCRs) are […]
Why IDO1 blockade lowered kynurenine but failed to improve anti-PDL1 efficacy in sarcoma
The Kynurenine Pathway as a possible resistance mechanism to immunotherapy in sarcomas
Background Sarcomas are heterogeneous malignant mesenchymal tumors known to be particularly resistant to immunotherapy. This resistance highlights the need to better understand the biological mechanisms limiting response to immune checkpoint inhibitors. We previously observed increased activity of the kynurenine pathway in the plasma of patients treated with pembrolizumab and metronomic cyclophosphamide. The kynurenine pathway is […]
Why melanoma escapes BRAF inhibitors — the AhR transcription factor behind resistance and relapse
